Skip to main content
SpringerLink
Log in

Dasatinib

  • Chapter
  • First Online:
Small Molecules in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 184))

Abstract

Dasatinib, (former BMS 354825), is an orally available small-molecule multikinase inhibitor. It potently inhibits BCR-ABL and SRC-family kinases (SRC, LCK, YES, FYN), but also c-KIT, PDGFR-α and β, and ephrin receptor kinase.

Dasatinib is about 300 times more potent than imatinib in cells expressing unmutated BCR-ABL in vitro. The drug has demonstrated activity against clinically relevant mutations, including those associated with poor prognosis during ongoing imatinib therapy.

Dasatinib is approved for the treatment of patients with BCR-ABL-positive chronic myeloid leukemia (CML), resistant or intolerant to imatinib in chronic, accelerated, and blast phase. It also is approved for the treatment of Philadelphia Chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to imatinib.

A single daily dose of 100 mg in chronic phase CML results in high hematologic and molecular remission rates and prolongation of survival. In accelerated and blastic phase as well as in ALL, 70 mg twice daily is recommended. Complete hematologic and cytogenetic remissions (CR) frequently occur even in this patient group with poor prognosis. Remissions however are very short.

Side effects of dasatinib are frequent but mostly moderate and manageable and include cytopenias and pleural effusions. The role of dasatinib in other diseases, including solid tumors, has to be identified.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 259.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akhmetshina A, Dees C, Pileckyte M et al (2008) Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 22: 2214–2222

    Article  PubMed  CAS  Google Scholar 

  • Apperley (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018–1029

    Google Scholar 

  • Baccarani M, Saglio G, Goldman J et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809–1820

    Article  PubMed  CAS  Google Scholar 

  • Borthakur G, Kantarjian HM, O’Brien S, et al (2008) Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). J Clin Oncol 26:15S:abstr. 7013

    Google Scholar 

  • Bose S, Deininger M, Gora-Tybor J et al (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362–3367

    PubMed  CAS  Google Scholar 

  • Bristol-Myers Squibb (2007) Dasatinib (Sprycel) Summary of product characteristics and prescribing information

    Google Scholar 

  • Chang Q, Jorgensen C, Pawson T et al (2008) Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 99:1074–1082

    Article  PubMed  CAS  Google Scholar 

  • Chen Z, Lee FY, Bhalla KN et al (2006) Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (Dasatinib). Mol Pharmacol 69: 1527–1533

    Article  PubMed  CAS  Google Scholar 

  • Copland M, Hamilton A, Elrick LJ et al (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532–4539

    Article  PubMed  CAS  Google Scholar 

  • Cortes J, Rousselot P, Kim DW et al (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207–3213

    Article  PubMed  CAS  Google Scholar 

  • Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008:1–8

    Google Scholar 

  • Cross NCP, Reiter A (2008) Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 119:199–206

    Article  PubMed  CAS  Google Scholar 

  • Daley GQ, Van Etten RA (1990) Induction of chronic myelogenous leukaemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ, Guilhot F, O’Brien S et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408–2417

    Article  PubMed  CAS  Google Scholar 

  • Evans TRJ, Morgan JA, Van den Abbeele AD, et al (2005) Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol 23:16S:abstr. 3034

    Google Scholar 

  • Fabarius A, Giehl M, Rebacz B et al (2008) Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 93: 1145–1154

    Article  PubMed  CAS  Google Scholar 

  • Faderl S, Kantarjian HM, Thomas DA et al (2000) Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36:263–273

    Article  PubMed  CAS  Google Scholar 

  • Finn RS, Dering J, Ginther C et al (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ ‘‘triple-negative’’ breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319–326

    Article  PubMed  CAS  Google Scholar 

  • Gambacorti-Passerini C, Gasser M, Ahmed S et al (2005) Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia 19:1267–1269

    Article  PubMed  CAS  Google Scholar 

  • Gambacorti C, Cortes J, Kim DW, et al (2007) Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program. Blood 110:abstr. 472

    Google Scholar 

  • Giles FJ, DeAngelo DJ, Baccarani M et al (2008) Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol 35(Suppl 1):S1–S17

    Article  CAS  Google Scholar 

  • Gratwohl A, Hermans J, Goldman JM et al (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352:1087–1092

    Article  PubMed  CAS  Google Scholar 

  • Guilhot F, Chastang C, Michallet M et al (1997) Interferon α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223–229

    Article  PubMed  CAS  Google Scholar 

  • Guilhot F, Apperley J, Kim DW et al (2007a) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143–4150

    Article  PubMed  CAS  Google Scholar 

  • Guilhot F, Apperley JF, Kim DW, et al (2007b) Efficacy of dasatinib in patients with. accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005). Blood 110:abstr. 470

    Google Scholar 

  • Hehlmann R, Heimpel H, Hasford J et al (1994) Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064–4077

    PubMed  CAS  Google Scholar 

  • Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710

    Article  PubMed  CAS  Google Scholar 

  • Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1316

    PubMed  CAS  Google Scholar 

  • Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    Article  PubMed  CAS  Google Scholar 

  • Hochhaus A (2007) Advances in the treatment of haematological malignancies: optimal sequence of CML treatment. Ann Oncol 18(Suppl 9): ix58–ix63

    Google Scholar 

  • Hochhaus A, Erben P, Ernst T et al (2007a) Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 44:15–24

    Article  CAS  Google Scholar 

  • Hochhaus A, Kantarjian HM, Baccarani M et al (2007b) Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303–2309

    Article  PubMed  CAS  Google Scholar 

  • Hochhaus A, Baccarani M, Deininger M et al (2008a) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200–1206

    Article  PubMed  CAS  Google Scholar 

  • Hochhaus A, Neubauer A, Mueller MC, et al (2008b) Imatinib discontinuation after imatinib/interferon alpha combination therapy is associated with continuous responses in the majority of patients. Haematologica 93:abstr. 0927

    Google Scholar 

  • Huang F, Reeves K, Han X et al (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67:2226–2238

    Article  PubMed  CAS  Google Scholar 

  • Jabbour E, Cortes J, O’Brien S et al (2007) New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance Semin Hematol 44:25–31

    Google Scholar 

  • Jayson GC, Parker GJM, Mullamitha S et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23:973–981

    Article  PubMed  CAS  Google Scholar 

  • Johnson FM, Saigal B, Talpaz M et al (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11:6924–6932

    Article  PubMed  CAS  Google Scholar 

  • Johnson FM, Chiappori A, Burris H, et al (2007) A phase I study (CA180021-segment 2) of dasatinib in patients (pts) with advanced solid tumors. J Clin Oncol 25:18S:abstr. 14042

    Google Scholar 

  • Kantarjian H, Pasquini R, Hammerschlak N et al (2007) Dasatinib or high-dose imatinib study for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 109:5143–5150

    Article  PubMed  CAS  Google Scholar 

  • Kopetz S, Shah AN, Gallick GE (2007) Src continues aging: current and future clinical directions. Clin Cancer Res 13(24):7232–7236

    Article  PubMed  CAS  Google Scholar 

  • Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475–486

    Article  PubMed  CAS  Google Scholar 

  • Lindahl P, Johannsson BR (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242–246

    Article  PubMed  CAS  Google Scholar 

  • Lombardo LJ, Lee FY, Chen P et al (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658–6661

    Article  PubMed  CAS  Google Scholar 

  • Nam S, Kim D, Cheng JQ et al (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65:9185–9189

    Article  PubMed  CAS  Google Scholar 

  • Nowell P, Hungerford DA (1960) A minute chromosome in human granulocytic leukemia. Science 132:1497

    Google Scholar 

  • O’Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500–4505

    Article  PubMed  Google Scholar 

  • Ottmann O, Dombret H, Martinelli G et al (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase II study. Blood 110: 2309–2315

    Article  PubMed  CAS  Google Scholar 

  • Park SI, Zhang JZ, Phillips KA et al (2008) Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68: 3323–3333

    Article  PubMed  CAS  Google Scholar 

  • Pasquini R, Ottmann OG, Goh YT, et al (2007) Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph (+) ALL resistant or intolerant to imatinib: one-year results of CA180–035. J Clin Oncol 25:18S:abstr. 7025

    Google Scholar 

  • Porkka K, Simonsson B, Dombret H, et al (2007) Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015). Blood 110:abstr. 2810

    Google Scholar 

  • Porkka K, Koskenvesa P, Lundan T et al (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukaemia. Blood 112:1005–1012

    Article  PubMed  CAS  Google Scholar 

  • Quintas-Cardama A, Kantarjian H, O’Brien S et al (2007a) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908–3914

    Article  PubMed  CAS  Google Scholar 

  • Quintas-Cardama A, Kantarjian H, O’Brien S, et al (2007b) Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukaemia. Haematologica 92(Suppl 1):abstr. 0359

    Google Scholar 

  • Schittenhelm MM, Shiraga S, Schroeder A et al (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66:473–481

    Article  PubMed  CAS  Google Scholar 

  • Serrels A, Macpherson IRJ, Evans TRJ et al (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 5:3014–3022

    Article  PubMed  CAS  Google Scholar 

  • Shah NP (2005) Loss of response to imatinib: mechanisms and management. The American society of hematology education program book. pp 183–187

    Google Scholar 

  • Shah NP, Tran C, Lee FY et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399–401

    Article  PubMed  CAS  Google Scholar 

  • Shah NP, Lee FY, Luo R et al (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108(1):286–291

    Article  PubMed  CAS  Google Scholar 

  • Shah NP, Kantarjian HM, Kim DM et al (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204–3212

    Article  PubMed  CAS  Google Scholar 

  • Shor AC, Keschman EA, Lee FY et al (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res 67:2800–2808

    Article  PubMed  CAS  Google Scholar 

  • Song L, Morris M, Bagui T et al (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66:5542–5548

    Article  PubMed  CAS  Google Scholar 

  • The Italian Cooperative Study Group on ChronicMyeloid Leukemia (1998) Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood 92:1541–1548

    Google Scholar 

  • Talpaz M, Shah NP, Kantarjian H et al (2006) dasatinib in imatinib-resistant philadelphia chromosome–positive leukemias. N Engl J Med 354: 2531–2541

    Article  PubMed  CAS  Google Scholar 

  • Tokarski JS, Newitt JA, Chang CYJ et al (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790–5797

    Article  PubMed  CAS  Google Scholar 

  • Verstovsek S, Tefferi A, Cortes J et al (2008) Phase II study of dasatinib in philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3907–3915

    Google Scholar 

  • Yu EY, Wilding G, Posadas E, et al (2008) Dasatinib in patients with hormone refractory progressive prostate cancer: a phase II study. J Clin Oncol 26:15S:abstr. 5165

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik III, SLK-Kliniken Heilbronn GmbH, Am Gesundbrunnen 20 – 26, Heilbronn, 74078, Germany

    Markus Lindauer

Authors
  1. Markus Lindauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Lindauer .

Editor information

Editors and Affiliations

  1. Medizinische Klinik III, SLK-Kliniken Heilbronn GmbH, Am Gesundbrunen 20-26, Heilbronn, 74078, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lindauer, M., Hochhaus, A. (2010). Dasatinib. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 184. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01222-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01222-8_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01221-1

  • Online ISBN: 978-3-642-01222-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation